Sector News

Actavis, Sanofi, Boehringer jockey bids for OTC specialist Omega Pharma

October 21, 2014
Life sciences
Actavis seems to have a finger in every pie lately when it comes to pharma M&A, and rumor has it Omega Pharma’s sales process is no exception.
 
The company is duking it out with Sanofi, Perrigo and Boehringer Ingelheim for the Belgian drugmaker, Bloomberg’s sources say, with final offers for Omega due by the beginning of November. Industry-watchers have said a sale could fetch as much as €4 billion, or $5.1 billion.
 
It’s just the latest clue into the deals Actavis may have up its sleeve. The company, which already has major pickups for Warner Chilcott and Forest Laboratories in its not-so-distant past, recently approached Valeant target Allergan about a deal, but the Botox-maker rebuffed it with the belief it was closing in on North Carolina-based Salix. So what did Actavis do next? Get busy talking with Salix on a deal of its own, of course.
 
But on the flip side, Actavis’ name has come up plenty on the other side of things, too, namely as a back-up target for Pfizer if it opts not to go after AstraZeneca  a second time. In late September, the news service reported that Pfizer was indeed shopping Actavis, but that talks didn’t appear active at the moment.
 
Whoever does land Omega will pick up some heft in the consumer health arena, with the company boasting about 2,000 brands. Its sales swelled 16% to €1.2 billion ($1.6 billion) last year thanks to strong performances in Germany, the U.K., Ireland, France, Russia and elsewhere.
 
And as the crowded bidding landscape shows, plenty of drugmakers wouldn’t mind adding that kind of top-line firepower in OTC. Sanofi has bulked up considerably over the last few years in that arena, and Novartis and GlaxoSmithKline will next year launch a consumer health JV that could make the team the field’s world leader. That’s a spot Bayer says it’s coveting, too, and to that end it nabbed Merck’s consumer unit in a $14.2 billion deal this May.
 
By Carly Helfand
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend